Technion researchers part of international study that validates fast, accessible alternative to genomic tests using routine ...
FY2025 revenue up 24%, margins expanding, backlog growing, and 25% upside to $13.05. Read the full analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results